|
1
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
|
|
2
|
de Camargo Cancela M, Voti L, Guerra-Yi M,
Chapuis F, Mazuir M and Curado MP: Oral cavity cancer in developed
and in developing countries: population-based incidence. Head Neck.
32:357–367. 2010.
|
|
3
|
INCA National Cancer Institute.
Estimate/2012-Cancer Incidence in Brazil. Ministry of Health;
Brasília, Brazil: pp. 982009
|
|
4
|
Gillison ML: Current topics in the
epidemiology of oral cavity and oropharyngeal cancers. Head Neck.
29:779–792. 2007.
|
|
5
|
Marques LA, Eluf-Neto J, Figueiredo RA,
Góis-Filho JF, Kowalski LP, Carvalho MB, Abrahão M and Wünsch-Filho
V: Oral health, hygiene practices and oral cancer. Rev Saude
Publica. 42:471–479. 2008.
|
|
6
|
Palka KT, Slebos RJ and Chung CH: Update
on molecular diagnostic tests in head and neck cancer. Semin Oncol.
35:198–210. 2008.
|
|
7
|
Hu S, Arellano M, Boontheung P, Wang J,
Zhou H, Jiang J, Elashoff D, et al: Salivary proteomics for oral
cancer biomarker discovery. Clin Cancer Res. 14:6246–6252.
2008.
|
|
8
|
Nagler RM: Saliva as a tool for oral
cancer diagnosis and prognosis. Oral Oncol. 45:1006–1010. 2009.
|
|
9
|
Douglas WG, Tracy E, Tan D, Yu J, Hicks WL
Jr, Rigual NR, Loree TR, et al: Development of head and neck
squamous cell carcinoma is associated with altered cytokine
responsiveness. Mol Cancer Res. 2:585–593. 2004.
|
|
10
|
Feller L, Altini M and Lemmer J:
Inflammation in the context of oral cancer. Oral Oncol. 49:887–892.
2013.
|
|
11
|
Candido J and Hagemann T: Cancer-related
inflammation. J Clin Immunol. 33(Suppl 1): S79–S84. 2013.
|
|
12
|
Mantovani A, Garlanda C and Allavena P:
Molecular pathways and targets in cancer-related inflammation. Ann
Med. 42:161–170. 2010.
|
|
13
|
Bloom BR and Bennett B: Mechanism of a
reaction in vitro associated with delayed-type hypersensitivity.
Science. 153:80–82. 1966.
|
|
14
|
David JR: Delayed hypersensitivity in
vitro: its mediation by cell-free substances formed by lymphoid
cell-antigen interaction. Proc Natl Acad Sci USA. 56:72–77.
1966.
|
|
15
|
Calandra T and Roger T: Macrophage
migration inhibitory factor: a regulator of innate immunity. Nat
Rev Immunol. 3:791–800. 2003.
|
|
16
|
Bucala R and Donnelly SC: Macrophage
migration inhibitory factor: a probable link between inflammation
and cancer. Immunity. 26:281–285. 2007.
|
|
17
|
Mitchell RA and Bucala R: Tumor
growth-promoting properties of macrophage migration inhibitory
factor (MIF). Semin Cancer Biol. 10:359–366. 2000.
|
|
18
|
Mitchell RA: Mechanisms and effectors of
MIF-dependent promotion of tumourigenesis. Cell Signal. 16:13–19.
2004.
|
|
19
|
Grieb G, Merk M, Bernhagen J and Bucala R:
Macrophage migration inhibitory factor (MIF): a promising
biomarker. Drug News Perspect. 23:257–264. 2010.
|
|
20
|
Yasasever V, Camlica H, Duranyildiz D,
Oguz H, Tas F and Dalay N: Macrophage migration inhibitory factor
in cancer. Cancer Invest. 25:715–719. 2007.
|
|
21
|
Muramaki M, Miyake H, Yamada Y and Hara I:
Clinical utility of serum macrophage migration inhibitory factor in
men with prostate cancer as a novel biomarker of detection and
disease progression. Oncol Rep. 15:253–257. 2006.
|
|
22
|
Lee H, Rhee H, Kang HJ, et al: Macrophage
migration inhibitory factor may be used as an early diagnostic
marker in colorectal carcinomas. Am J Clin Pathol. 129:772–779.
2008.
|
|
23
|
He XX, Yang J, Ding YW, Liu W, Shen QY and
Xia HH: Increased epithelial and serum expression of macrophage
migration inhibitory factor (MIF) in gastric cancer: potential role
of MIF in gastric carcinogenesis. Gut. 55:797–802. 2006.
|
|
24
|
Meyer-Siegler KL, Bellino MA and
Tannenbaum M: Macrophage migration inhibitory factor evaluation
compared with prostate specific antigen as a biomarker in patients
with prostate carcinoma. Cancer. 94:1449–1456. 2002.
|
|
25
|
Hira E, Ono T, Dhar DK, El-Assal ON,
Hishikawa Y, Yamanoi A and Nagasue N: Overexpression of macrophage
migration inhibitory factor induces angiogenesis and deteriorates
prognosis after radical resection for hepatocellular carcinoma.
Cancer. 103:588–598. 2005.
|
|
26
|
Xia HH, Yang Y, Chu KM, Gu Q, Zhang YY, He
H, Wong WM, et al: Serum macrophage migration-inhibitory factor as
a diagnostic and prognostic biomarker for gastric cancer. Cancer.
115:5441–5449. 2009.
|
|
27
|
Kindt N, Lechien J, Decaestecker C,
Rodriguez A, Chantrain G, Remmelink M, Laurent G, et al: Expression
of macrophage migration-inhibitory factor is correlated with
progression in oral cavity carcinomas. Anticancer Res.
32:4499–4505. 2012.
|
|
28
|
Hudson JD, Shoaibi MA, Maestro R, Carnero
A, Hannon GJ and Beach DH: A proinflammatory cytokine inhibits p53
tumor suppressor activity. J Exp Med. 190:1375–1382. 1999.
|
|
29
|
Denz A, Pilarsky C, Muth D, Rückert F,
Saeger HD and Grützmann R: Inhibition of MIF leads to cell cycle
arrest and apoptosis in pancreatic cancer cells. J Surg Res.
160:29–34. 2010.
|
|
30
|
Li GQ, Xie J, Lei XY and Zhang L:
Macrophage migration inhibitory factor regulates proliferation of
gastric cancer cells via the PI3K/Akt pathway. World J
Gastroenterol. 15:5541–5548. 2009.
|
|
31
|
Schrader J, Deuster O, Rinn B, Schulz M,
Kautz A, Dodel R, Meyer B, et al: Restoration of contact inhibition
in human glioblastoma cell lines after MIF knockdown. BMC Cancer.
9:4642009.
|
|
32
|
Rendon BE, Willer SS, Zundel W and
Mitchell RA: Mechanisms of macrophage migration inhibitory factor
(MIF)-dependent tumor microenvironmental adaptation. Exp Mol
Pathol. 86:180–185. 2009.
|
|
33
|
Calandra T, Bernhagen JL, Mitchell RA and
Bucala R: The macrophage is an important and previously
unrecognized source of macrophage migration inhibitory factor. J
Exp Med. 179:1895–1902. 1994.
|
|
34
|
Camlica H, Duranyildiz D, Oguz H, Oral EN
and Yasasever V: The diagnostic value of macrophage migration
inhibitory factor (MIF) in gastric cancer. Pathol Oncol Res.
14:79–83. 2008.
|
|
35
|
Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang
S, Xie S, et al: Transcriptional patterns, biomarkers and pathways
characterizing nasopharyngeal carcinoma of Southern China. J Transl
Med. 6:322008.
|
|
36
|
Kamimura A, Kamachi M, Nishihira J, Ogura
S, Isobe H, Dosaka-Akita H, Ogata A, et al: Intracellular
distribution of macrophage migration inhibitory factor predicts the
prognosis of patients with adenocarcinoma of the lung. Cancer.
89:334–341. 2000.
|
|
37
|
Mohri Y, Mohri T, Wei W, Qi YJ, Martin A,
Miki C, Kusunoki M, et al: Identification of macrophage migration
inhibitory factor and human neutrophil peptides 1–3 as potential
biomarkers for gastric cancer. Br J Cancer. 101:295–302. 2009.
|
|
38
|
Ren Y, Law S, Huang X, Lee PY, Bacher M,
Srivastava G and Wong J: Macrophage migration inhibitory factor
stimulates angiogenic factor expression and correlates with
differentiation and lymph node status in patients with esophageal
squamous cell carcinoma. Ann Surg. 242:55–63. 2005.
|
|
39
|
Tomiyasu M, Yoshino I, Suemitsu R, Okamoto
T and Sugimachi K: Quantification of macrophage migration
inhibitory factor mRNA expression in non-small cell lung cancer
tissues and its clinical significance. Clin Cancer Res.
8:3755–3760. 2002.
|
|
40
|
Xia HH, Zhang ST, Lam SK, Lin MC, Kung HF
and Wong BC: Expression of macrophage migration inhibitory factor
in esophageal squamous cell carcinoma and effects of bile acids and
NSAIDs. Carcinogenesis. 26:11–15. 2005.
|
|
41
|
Cooke G, Armstrong ME and Donnelly SC:
Macrophage migration inhibitory factor (MIF), enzymatic activity
and the inflammatory response. Biofactors. 35:165–168. 2009.
|
|
42
|
Sanchez-Zamora Y, Terrazas LI,
Vilches-Flores A, et al: Macrophage migration inhibitory factor is
a therapeutic target in treatment of non-insulin-dependent diabetes
mellitus. FASEB J. 24:2583–2590. 2010.
|
|
43
|
Bucala R: MIF Rediscovered. MIF, A Most
Interesting Factor. World Scientific Press; London: 2007
|
|
44
|
Baugh JA, Chitni S, Donnelly SC, et al: A
functional promoter polymorphism in the macrophage migration
inhibitory factor (MIF) gene associated with disease severity in
rheumatoid arthritis. Genes Immun. 3:170–176. 2002.
|
|
45
|
Donn RP, Shelley E, Ollier WE, et al: A
novel 5′-flanking region polymorphism of macrophage migration
inhibitory factor is associated with systemic-onset juvenile
idiopathic arthritis. Arthritis Rheum. 44:1782–1785. 2001.
|
|
46
|
Sun B, Nishihira J, Yoshiki T, et al:
Macrophage migration inhibitory factor promotes tumor Invasion and
metastasis via the Rho-dependent pathway. Clin Cancer Res.
11:1050–1058. 2005.
|
|
47
|
Funamizu N, Hu C, Lacy C, Schetter A,
Zhang G, He P, et al: Macrophage migration inhibitory factor (MIF)
induces epithelial to mesenchymal transition, enhances tumor
aggressiveness and predicts clinical outcome in resected pancreatic
ductal adenocarcinoma. Int J Cancer. Jul 23–2013.(Epub ahead of
print).
|
|
48
|
Han I, Lee MR, Nam KW, Oh JH, Moon KC and
Kim HS: Expression of macrophage migration inhibitory factor
relates to survival in high-grade osteosarcoma. Clin Orthop Relat
Res. 466:2107–2113. 2008.
|
|
49
|
Liu H, Chen G, Zhang W, et al:
Overexpression of macrophage migration inhibitory factor in adenoid
cystic carcinoma: correlation with enhanced metastatic potential. J
Cancer Res Clin Oncol. 139:287–295. 2013.
|
|
50
|
Suzuki F, Nakamaru Y, Oridate N, Homma A,
Nagahashi T, Yamaguchi S, Nishihira J, et al: Prognostic
significance of cytoplasmic macrophage migration inhibitory factor
expression in patients with squamous cell carcinoma of the head and
neck treated with concurrent chemoradiotherapy. Oncol Rep.
13:59–64. 2005.
|
|
51
|
Verjans E, Noetzel E, Bektas N, Schütz AK,
Lue H, Lennartz B, Hartmann A, et al: Dual role of macrophage
migration inhibitory factor (MIF) in human breast cancer. BMC
Cancer. 9:2302009.
|
|
52
|
Lim S, Choong LY, Kuan CP, Yunhao C and
Lim YP: Regulation of macrophage inhibitory factor (MIF) by
epidermal growth factor receptor (EGFR) in the MCF10AT model of
breast cancer progression. J Proteome Res. 8:4062–4076. 2009.
|
